StockData
Alpha Cognition Inc. logo

Alpha Cognition Inc. (ACOG) stock

ACOGNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3060% above fair value
$7.83−0.47 (-5.66%)

Close on Nov 16, 2026Market cap $170.52MP/E –Yield –

Earnings

Alpha Cognition's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue, Q4 FY2025
$2.50M
EPS, Q4 FY2025
–
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Alpha Cognition's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2025ended Dec 31, 2025Mar 26, 2026after the close$2.50M––Release
Q2 FY2024ended Jun 30, 2024Aug 13, 2024after the close––-$0.01Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Alpha Cognition has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Alpha Cognition puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Alpha Cognition filed with the SEC as exhibits to Form 8-K or 6-K

See a number that looks wrong?